Brighter's management and board fully subscribes in the ongoing exercise period of TO3 warrants.

Brighter's management, including the CEO and COO, and all board members of the company has decided to fully subscribe to their share of the TO3 warrants. These subscriptions represent 7.16 % of the total number of TO3 warrants and amount to a total value of 1 902 560 SEK. The subscription price has been set at 4 SEK.

– Over the last two years we have made major progress, which means that we are now entering the launch phase with very good prospects of success, says Brighter's CEO and founder Truls Sjöstedt. With this solid foundation, we will now focus on launching our unique diabetes solution Actiste in Sweden and Asia, where the Asian market has the greatest potential. Our recently granted patent in the United States also opens up the huge US diabetes market. In all we have a very positive view of the future.

The subscription period is ongoing and expires on October 25, 2017. Shareholders wishing to subscribe during this period should contact their trustee immediately.

The subsequent five exercise periods are:

11 - 25 April 2018
11 - 25 October 2018
11 - 25 April 2019
11 - 25 October 2019
10 - 24 April 2020

For terms and conditions of the Warrants, please visit: http://brighter.se/en/investors/documents/

For more information, please contact:

Truls Sjöstedt, CEO       
Tel: +46 709 73 46 00       
Email: truls.sjostedt@brighter.se

Henrik Norström, COO       
Tel: +46 733 40 30 45       
Email: henrik.norstrom@brighter.se

About Brighter AB (publ)       
Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms.

The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com.

About Us

Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of the most serious healthcare problems: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop™ - is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and close associates, healthcare providers, research, pharmaceutical industry and society. Website: https://brighter.se/ The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB +46 (0)8 – 684 211 00, info@eminova.se, www.eminova.se

Subscribe

Documents & Links